Financial Performance - The company's operating revenue for Q1 2024 was ¥978,184,584.19, representing a 5.09% increase compared to ¥930,792,120.15 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2024 was ¥155,917,808.87, up 3.75% from ¥150,279,161.27 in Q1 2023[3]. - The net profit after deducting non-recurring gains and losses was ¥157,336,643.80, reflecting a 6.89% increase from ¥147,199,342.42 year-on-year[3]. - Total revenue for Q1 2024 reached ¥978,184,584.19, an increase of 5.5% compared to ¥930,792,120.15 in Q1 2023[14]. - The net profit for Q1 2024 was CNY 164,788,049.79, an increase from CNY 157,743,872.79 in Q1 2023, representing a growth of approximately 6.6%[15]. - The total operating profit for the quarter was CNY 233,868,400.08, slightly up from CNY 231,979,184.86 in the same period last year, showing a marginal increase of about 0.8%[15]. - The company reported a total comprehensive income of CNY 164,644,187.74 for Q1 2024, compared to CNY 157,743,872.79 in Q1 2023, indicating an increase of approximately 4.8%[16]. Cash Flow and Assets - The net cash flow from operating activities decreased by 34.75% to ¥176,877,677.26, down from ¥271,087,408.44 in the previous year[3]. - Cash and cash equivalents decreased to ¥1,828,698,603.69 from ¥3,917,302,307.73, indicating a decline of 53.3%[12]. - The ending cash and cash equivalents balance was CNY 1,814,263,256.75, down from CNY 2,940,102,692.11 at the end of Q1 2023, representing a decrease of approximately 38.3%[18]. - The net cash flow from investing activities was -CNY 2,077,787,213.94, a significant decrease from CNY 1,361,244,349.59 in the previous year, reflecting a change of approximately 253.5%[18]. - Cash inflow from investment activities totaled CNY 363,075,018.94, down from CNY 2,813,295,828.58 in Q1 2023, showing a decline of around 87.1%[18]. - Cash outflow from investment activities reached CNY 2,440,862,232.88, compared to CNY 1,452,051,478.99 in the same quarter last year, marking an increase of approximately 67.9%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,212[7]. - The largest shareholder, Huaxia Medical Investment (Xiamen) Co., Ltd., holds 30.45% of the shares, totaling 255,764,011 shares[7]. - The second-largest shareholder, Su Qingcan, directly holds 30.41% of the shares, totaling 255,405,989 shares[8]. - Su Qingcan, through direct and indirect means, holds a total of 55.98% of the company's shares[8]. - The company plans to repurchase shares with a total fund of no less than 150 million yuan and no more than 250 million yuan[11]. - As of the report date, the company has repurchased 5,225,140 shares, accounting for 0.62% of the total share capital[11]. - The total amount spent on repurchased shares was 150.99 million yuan (excluding transaction fees)[11]. Expenses and Liabilities - Total operating costs for Q1 2024 were ¥764,366,715.10, up from ¥715,615,468.19 in the same period last year, reflecting a year-over-year increase of 6.8%[14]. - Sales expenses increased to CNY 124,981,288.32 from CNY 108,052,351.60, representing a rise of about 15.7%[15]. - The company’s financial expenses decreased to CNY 5,660,595.06 from CNY 6,167,687.04, a reduction of approximately 8.2%[15]. - Total liabilities increased to ¥1,730,734,293.22 from ¥1,661,173,884.62, reflecting a rise of 4.2%[14]. - Current liabilities decreased to ¥974,553,679.36 from ¥1,003,505,397.30, a reduction of 2.9%[14]. Other Information - The company has not received any investigation or cooperation documents from authorities regarding the personal situation of its actual controller, Su Qingcan[11]. - The company has not disclosed any new product or technology developments, market expansion, or mergers and acquisitions in this report[11]. - The company did not conduct an audit for the Q1 2024 report[19].
华厦眼科(301267) - 2024 Q1 - 季度财报